Journal
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE
Volume 69, Issue 3, Pages 342-347Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.diagmicrobio.2010.10.031
Keywords
Dalbavancin; Telavancin; Vancomycin
Categories
Ask authors/readers for more resources
Two novel lipoglycopeptides, dalbavancin and telavancin, and relevant comparative agents were tested for in vitro activity against clinical isolates of staphylococci and streptococci collected in the cross-Canada surveillance study, CAN WARD, in 2007-2009. The rank order of potency (based on MIC90 [mu g/mL], i.e., the concentration of antimicrobial agent required to inhibit the growth of 90% of isolates tested) of glycopeptides against both Staphylococcus aureus and Staphylococcus epidermidis was dalbavancin (0.06 mu g/mL) >telavancin (0.5 mu g/mL) > vancomycin (1-2 mu g/mL); concurrent susceptibility or resistance to oxacillin in staphylococci did not affect potency of glycopeptides. Dalbavancin and telavancin also demonstrated potent activity against Streptococcus pneumoniae, including penicillin-resistant isolates (MIC90, <= 0.03 mu g/mL; <= 0.06 mu g/mL), and Streptococcus pyogenes (<= 0.03 mu g/mL; 0.06 mu g/mL). Based on their robust in vitro activities, dalbavancin and telavancin have the potential to treat Gram-positive infections caused by methicillin-resistant Staphylococcus aureus and penicillin-resistant Streptococcus pneumoniae. (C) 2011 Elsevier Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available